

CORRECTION

Open Access



# Correction to: Investigation of antimicrobial susceptibility, class I and II integrons among *Pseudomonas aeruginosa* isolates from hospitalized patients in Isfahan, Iran

Jamshid Faghri<sup>1</sup>, Samereh Nouri<sup>2</sup>, Saba Jalalifar<sup>1</sup>, Mehrdad Zalipoor<sup>1</sup> and Mehrdad Halaji<sup>3\*</sup>

## Correction to: BMC Res Notes (2018) 11:806

<https://doi.org/10.1186/s13104-018-3901-9>

Following publication of the original article [1], an error was reported in the tables due to a typesetting mistake. Table 3 is presented as a duplicate of Table 2. In this Correction, the correct presentation of Table 3 is shown.

The publisher apologises to the authors and readers for the inconvenience.

## Author details

<sup>1</sup> Department of Microbiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran. <sup>2</sup> Department of Microbiology, Clinical Laboratory of ALZAHRA Medical Center, Isfahan, Iran. <sup>3</sup> Students Research Committee, Isfahan University of Medical Sciences, Hezar Jarib St, Isfahan, Iran.

The original article can be found online at <https://doi.org/10.1186/s13104-018-3901-9>.

**Table 3 Antibiotic susceptibility pattern of class 2 integron-positive and integron-negative of *P. aeruginosa* strains**

Antibiotics	Integron-2 positive n = 21 No. (%)	Integron-2 negative n = 51 No. (%)	p-value
Meropenem	14 (66.6)	29 (57)	0.4
Cefepime	15 (71.4)	37 (72.5)	0.9
Ceftazidime	15 (71.4)	40 (78.5)	0.5
Piperacillin/tazobactam	10 (47.6)	25 (49)	0.9
Ciprofloxacin	16 (76.2)	37 (72.5)	0.7
Levofloxacin	14 (66.6)	37 (72.5)	0.6
Amikacin	11 (52.4)	19 (37.2)	0.3
Colistin	0	0	–

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 23 January 2019 Accepted: 23 January 2019

## Reference

1. Faghri J, Nouri S, Jalalifar S, Zalipoor M, Halaji M. Investigation of antimicrobial susceptibility, class I and II integrons among *Pseudomonas aeruginosa* isolates from hospitalized patients in Isfahan, Iran. BMC Res Notes. 2018;11:806. <https://doi.org/10.1186/s13104-018-3901-9>.

\*Correspondence: m.hallaji@resident.mui.ac.ir;  
mehrdad.md69@gmail.com

<sup>3</sup> Students Research Committee, Isfahan University of Medical Sciences,  
Hezar Jarib St, Isfahan, Iran

Full list of author information is available at the end of the article

